A Three-Part, Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-HBVS in Healthy Volunteers and Patients With Chronic Hepatitis B
Latest Information Update: 19 Jul 2024
Price :
$35 *
At a glance
- Drugs Xalnesiran (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Proof of concept
- Sponsors Dicerna Pharmaceuticals; Novo Nordisk
- 28 Sep 2022 Status changed from active, no longer recruiting to completed.
- 14 Oct 2021 According to a Dicerna Pharmaceuticals media release, data from this study will be presented at the 2021 American Association for the Study of Liver Diseases (AASLD) The Liver Meeting.
- 16 Nov 2020 Results published in the Dicerna Pharmaceuticals Media Release.